Displaying results 1 - 2 of 2
Clear search
RxCelerate launches Galaxy™: a next-generation antibody discovery platform
RxCelerate, a leading international out-sourced drug discovery and development platform, today revealed details of a new antibody discovery platform, Galaxy™, that offers significant advantages over the current generation of tools for delivery of new therapeutic monoclonal antibodies.
RxCelerate acquires cutting-edge molecular modelling company Prosarix
RxCelerate, one of the leading out-sourced drug discovery and development platforms in the UK, announced that it has acquired UK-based molecular modelling company Prosarix.